1152093-60-1

Basic information

• Product Name: tert-butyl 4-(6-bromopyridin-2-yl)-1,4-diazepane-1-carboxylate
• Synonyms: tert-butyl 4-(6-bromopyridin-2-yl)-1,4-diazepane-1-carboxylate
• CAS NO: 1152093-60-1
• Molecular Formula: C15H22BrN3O2
• Molecular Weight: 356
• Mol File: 1152093-60-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 458.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.333±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 4.10±0.19(Predicted)
• CAS DataBase Reference: tert-butyl 4-(6-bromopyridin-2-yl)-1,4-diazepane-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(6-bromopyridin-2-yl)-1,4-diazepane-1-carboxylate(1152093-60-1)
• EPA Substance Registry System: tert-butyl 4-(6-bromopyridin-2-yl)-1,4-diazepane-1-carboxylate(1152093-60-1)

Safety Data

• Hazardous Substances Data: 1152093-60-1(Hazardous Substances Data)

Usage

General Description

Tert-butyl 4-(6-bromopyridin-2-yl)-1,4-diazepane-1-carboxylate is a chemical compound that belongs to the class of organic compounds known as diazepanes, which are compounds containing a diazepane ring, a seven-membered monocyclic heterocycle with one nitrogen atom and six carbon atoms. This particular compound contains a tert-butyl group, a 4-(6-bromopyridin-2-yl) substituent, and a carboxylate group. It is commonly used as a building block in the synthesis of various pharmaceuticals and organic compounds due to its unique structure and chemical properties.

Upstream product

• 144100-07-2 2-bromo-6-fluoropyridine 
• 112275-50-0 tert-butyl 1,4-diazepine-1-carboxylate 

Relevant articles and documents

Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized Bioavailability

Pim kinases have been identified as promising therapeutic targets for hematologic-oncology indications, including multiple myeloma and certain leukemia. Here, we describe our continued efforts in optimizing a lead series by improving bioavailability while maintaining high inhibitory potency against all three Pim kinase isoforms. The discovery of extensive intestinal metabolism and major metabolites helped refine our design strategy, and we observed that optimizing the pharmacokinetic properties first and potency second was a more successful approach than the reverse. In the resulting work, novel analogs such as 20 (GNE-955) were discovered bearing 5-azaindazole core with noncanonical hydrogen bonding to the hinge.

INHIBITORS OF SPHINGOSINE KINASE

The present invention relates to compounds of the formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, M1, M2, M3, M4, Y1, Y2, V, W, n, m and o have the meanings given in Claim 1, and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for use in the treatment of diseases which are influenced by inhibition of Sph kinase 1.